HONG KONG SAR – Media OutReach Newswire – 16 October 2026 – HKSH Cancer Centre, a member of HKSH Medical Group (HKSH), was invited to take part in the World Cancer Congress 2026 held from 24 to 26 September, one of the world’s most influential conferences on cancer control. The Union for International Cancer Control (UICC) and the Hong Kong Anti-Cancer Society (HKACS) co-hosted the Congress, which was held for the first time in Hong Kong, bringing together delegates from over 120 regions and countries for global exchange. HKSH took part under the theme “Beat Cancer, Fight Smarter” and presented its clinical experience, research, and technology innovations in the fight against cancer. Building on this momentum, and in support of the national Healthy China strategy, HKSH will co-host the 6^th China Particle Radiotherapy Conference with the Shanghai Proton and Heavy Ion Center from 16 to 18 October 2026. International experts will speak at the Conference and share their experience with peers from the Mainland. These events reflect HKSH’s commitment to advancing clinical and research together and to leading the development of precision medicine.

Mr. Wyman LI, Governor of The Li Shu Fan Medical Foundation, Chief Operating Officer of HKSH Medical Group and Director of Hong Kong Sanatorium & Hospital, said, “HKSH Cancer Centre has always been at the forefront of advanced cancer management. We pioneer precision medicine, by bringing in state-of-the-art medical technologies and equipment, combined with cutting-edge scientific research, global academic exchange and the cultivation of medical professionals, to shape the future of cancer care. We believe that clinical practice inspires research while research advances healthcare, driving us to enhance diagnosis and treatment services for cancer patients. HKSH has notched up numerous achievements that lead the way in Hong Kong and Asia, casting an impact in cancer management.”

Dr. Walton LI, Chairman of The Li Shu Fan Medical Foundation, Chief Executive Officer of HKSH Medical Group and Medical Superintendent of Hong Kong Sanatorium & Hospital, remarked, “HKSH is honoured to participate in the World Cancer Congress 2026 held in Hong Kong for the first time. This is not only an affirmation of the academic standing of Hong Kong’s medical community, but also a valuable opportunity for Hong Kong to connect with international leading experts and facilitate cross-regional anti-cancer collaboration, translating advanced technologies into tangible clinical outcomes. HKSH Cancer Centre is equipped with state-of-the-art and comprehensive facilities for diagnosing and treating cancer as well as multi-disciplinary teams that provide one-stop, personalised cancer management services. HKSH Cancer Centre is committed to becoming one of the world’s leading cancer management hubs.”

HKSH Cancer Centre in Pursuit of Ultra Precision and Clinical Excellence
To address the complex challenges of disease management, HKSH Cancer Centre drives ultra-precision, monitoring the genetic profile and the diseases using state-of-the-art technologies. We offer one-stop care from early screening and accurate diagnosis to a wide range of advanced treatments and full patient support. The key to effective disease management lies in the seamless integration and precise coordination between various specialties. Imaging diagnosis, molecular pathology, nuclear medicine, surgery, radiotherapy, immunotherapy and new drugs are combined according to each patient’s condition to deliver precise treatment and attentive care.

• Accurate Diagnosis for Timely Action: HKSH Cancer Centre offers comprehensive cancer genomic testing, backed by leading molecular pathology testing, to fully understand the genetic characteristics of tumours. HKSH also introduced Hong Kong’s first total-body PET/CT system and Asia’s first Photon-Counting CT Simulator system (PCCT-Sim). These systems show the full extent of tumours, which supports early diagnosis and precise genetic analysis, so that patients can be matched with the most suitable treatment plans.
• Advanced Therapies that Keep Improving:HKSH is in the constant pursuit of treatment excellence. Since introducing the first proton therapy system in the Greater Bay Area in 2023, HKSH has accumulated extensive experience by performing over 1,000 proton therapy cases. To continuously improve the precision of proton therapy, the team actively explores more cost-effective “hypofractionation” treatment approach. Recently, the team has further integrated PCCT-Sim for pre-treatment planning, enabling higher doses of radiation to more precisely target tumours. This enhances treatment efficacy while significantly reducing the number of treatment sessions, minimising side effects and benefitting more patients.
• Medical Research and Training:HKSH Clinical Trials Centre was established in 2017, while HKSH Comprehensive Oncology Centre was accredited by the National Medical Products Administration in 2019, making HKSH the only private medical institution in Hong Kong to receive this qualification.Through the establishment of HKSH Institute for Innovation & Professional Development, HKSH is committed to advancing medical education, while also shouldering the important task of national proton therapy talent training. It collaborated with the National Cancer Center last year to launch a joint training and ten-month specialised programme, helping to elevate the overall standard of proton therapy in the region and bringing patients more precise and cost-effective disease management services.

Active Participation in World Cancer Congress to Demonstrate World-Class Strength in Precision Medicine
At the World Cancer Congress, HKSH Cancer Centre presented a cross-disciplinary session under the theme of “Beat Cancer, Fight Smarter”, leveraging its strong clinical and research support. The session was titled “Advances in Diagnostics: Guiding Modern Cancer Therapeutics”, covering the evolution of real-time response-adaptive radiotherapy (cancer treatment), new integrated model of cancer diagnosis and treatment (nuclear medicine), and comprehensive cancer genomic testing-guided precision treatment (molecular pathology). The guest speakers from HKSH shared clinical experience and research findings with leading oncology experts and scholars from around the world.

In the session “Clinical Applications of Photon-Counting CT and MR-Guided Radiotherapy in Oncology”, Dr. Amy CHANG, Co-Director of HKSH Proton Therapy Centre and Specialist in Clinical Oncology, HKSH Medical Group, said “PCCT-Sim provides higher resolution, which helps reduce uncertainty in proton therapy and protect vital tissues. Real-time magnetic-resonance (MR) guidance can narrow the radiotherapy target to the exact tumour area. This lets us safely give higher doses to the tumour and makes a hypofractionated approach possible.” HKSH Cancer Centre has used this approach for suitable patients with breast cancer and prostate cancer.

Dr. Garrett HO, Head of Department of Nuclear Medicine and Positron Emission Tomography and Specialist in Nuclear Medicine, HKSH Medical Group, gave a talk titled “The Theranostic Landscape of PET/CT Advances: From Benchtop Science to Practical Clinical Utility”. He reviewed the history of PET imaging and its major advances in cancer care, where HKSH opened Asia’s first PET Centre in 1999, now producing more than 30 PET tracers and radiopharmaceuticals and becoming one of the few centres in the region with full nuclear medicine service. Dr. HO said, “The Total-body PET/CT recently introduced in Hong Kong shortens whole-body scan time from 20 minutes to about 5 minutes and lowers the radiation dose for patients. Together with tracer technology, it helps us detect cancer cells more clearly and more efficiently, from early to advanced stages.”

In 2011, HKSH became the first private healthcare institution in Hong Kong to introduce next-generation sequencing (NGS). Currently, HKSH is the only private medical institution in Hong Kong that offers in-house comprehensive cancer genomic testing. Dr. Edmond MA, Director of Clinical Pathology & Molecular Pathology Division and Specialist in Haematology, HKSH Medical Group, spoke on “Molecular Diagnostic Pathology at the Frontier of Precision Oncology”, said “Compared with sending samples out, in-house comprehensive genomic profiling services enable the entire process, from tissue sampling and laboratory testing to final analysis, to be conducted in-house which allows us to provide timely, in-depth genetic analysis sooner for patients with advanced stages or complex conditions. It also helps us track how well treatment is working and spot drug resistance.”

Dr. Raymond LIANG, Director of HKSH Comprehensive Oncology Centre and Specialist in Haematology & Haematological Oncology, HKSH Medical Group, who chaired the session, said in his closing remarks, “In the era of precision medicine, clinicians, researchers, and technology experts work together to make the best use of research-driven technologies. At HKSH Cancer Centre, our ultimate goal is to benefit patients, by offering personalised care that brings both effective treatment outcomes and a good quality of life even in complex and advanced disease.”.

Please click here to watch the video of HKSH Cancer Centre.

Hashtag: #HKSH

The issuer is solely responsible for the content of this announcement.

BANGKOK, THAILAND – Media OutReach Newswire – 16 October 2026 – Access to nutritious food remains a critical part of food security. In Thailand, around one in 10 children under five lives in severe child food poverty, while national data show that 13% of children under five are stunted and 7% are underweight, underscoring that food security is not only about having enough food, but also about ensuring consistent access to safe and nutritious diets.

Against this backdrop, Charoen Pokphand Foods Public Company Limited (CPF), in partnership with the Charoen Pokphand for Rural Lives’ Development Foundation, is expanding the “Eggs for Next Gen” program, a long-running school nutrition initiative, to 1,030 schools across Thailand, with 12 new schools joining this year. The expansion builds on nearly four decades of efforts to help children gain regular access to fresh eggs as a source of quality protein, while enabling schools to establish sustainable food production.

Launched in 1989, the program goes beyond providing food for school lunches. Participating schools receive support including poultry houses, equipment, laying hens and feed, together with technical knowledge in animal health, farm management, sanitation, production planning and egg management. Students and teachers gain practical agricultural skills, while schools can use eggs for meals and manage surplus production to generate revolving income that helps sustain future production cycles.

The initiative had reached 1,030 schools across 74 provinces, benefiting more than 229,502 students, 17,447 academic staff and2,690 communities. More than523 persons with disabilitieshave also participated in the programme, which targets approximately28 million eggs per production cycle.

Eggs for Next Gen reflects CPF’s broader view that food security depends not only on producing enough food, but on making nutritious food consistently available, accessible and sustainable over time. By helping schools produce fresh eggs locally, the programme brings quality protein closer to children, supports healthier diets, and builds practical knowledge and capabilities that allow schools to maintain food production beyond a single cycle. In this way, the initiative moves beyond short-term food support toward stronger food self-reliance at the school and community level.

As a global integrated agro-industrial and food company with operations and investments across 17 countries and products distributed in more than 50 countries, CPF advances its “Kitchen of the World” vision by placing food security at the heart of its sustainability strategy. Its global presence helps expand access to food for consumers worldwide, while its approach goes beyond producing sufficient food to strengthen quality and food safety, nutrition, responsible production and sustainable supply chains. Together, these efforts support a more resilient and sustainable food system capable of serving people over the long term.

Kobboon Srichai, Head of Corporate Affairs and Investor Relations at CPF, said:

“For CPF, food security means ensuring that people can access food that is safe, traceable and affordable today and in the future. To achieve this, we need to strengthen the entire food system, from production to access. By combining technology and automation, strong partnerships, and advances in biotechnology and nutrition, we can improve both the quality and resilience of the food system. Eggs for Next Gen demonstrates how these capabilities can be translated into practical impact, improving children’s access to quality nutrition while helping schools and communities build greater food self-reliance over the long term.”

With the program now expanding to 1,030 schools, CPF continues to translate its food expertise into practical action. Supporting healthier children, stronger communities and a more resilient and sustainable food system.

Hashtag: #CPF #Zerohunger #WorldFoodDay2026 #FoodSecurity #FoodAccessForAll #SustainableFoodSystems #CPFSustainability

The issuer is solely responsible for the content of this announcement.

HONG KONG SAR – Media OutReach Newswire – 16 October 2026 – IX Asia Indexes today announced the 2026 third quarter review of the ixCrypto Index Series. The review results are as follows:

1. Constituent Review – ixCrypto Index Series

1.1. ixCrypto Index (“IXCI”)
The number of constituents remains unchanged at 19.

Additions
1. No addition

Deletions
1. No deletion

After the change, the free float adjusted market capitalization coverage is 83.86%* (excluding stablecoins, which have 11.58% of the total crypto universe), while the 90-day-average volume coverage is 71.12%*. The recapping at 40% will take effect on 23rd October 2026 (Friday).

Since the last review, crypto total market capitalization increased from USD2.43T to USD2.44T (+0.37%)^#, while daily volume decreased from USD96.89B to USD73.25B

(-24.40%)^#. Bitcoin remains the largest crypto in the constituent list, with its price increasing by 38.94% since the last review.

1.2. ixCrypto Portfolio Indexes

1.2.1 ixCrypto 5 Equal Weight Index (“IXEW5”) and ixCrypto 5 Square Root Index (“IXSR5”)

Addition
No addition

Deletion
No deletion

1.2.2 ixCrypto 10 Equal Weight Index (“IXEW10”) and ixCrypto 10 Square Root Index (“IXSR10”).

Additions
1. Monero

Deletions
1. Cardano

1.2.3 ixCrypto Altcoin 10 EW Index (“IXAEW10”) and ixCrypto Altcoin 10 SR Index (“IXASR10”).

Additions

1. Monero
2. Chainlink

Deletions

1. Cardano
2. Bitcoin Cash

1.3. ixCrypto BTC/ETH Indexes
As of the cut-off date on 30th September 2026, the ixCrypto BTC/ETH 50/50 Index (“IX5050”) maintains a 50%/50% weighting for the ixBitcoin Index (IXBI) and ixEthereum Index (IXEI). The ixCrypto BTC/ETH Proportional Index (“IXPI”) has the previous effective weighting of 86.12% and 13.88% for IXBI and IXEI, respectively.

At the upcoming effective date, IX5050 weightings will remain unchanged at 50%/50%. IXPI weightings will be adjusted to 83.67% and 16.33% for IXBI and IXEI, respectively, reflecting the market capitalization proportions of Bitcoin and Ethereum at the cut-off date.

2. Constituent Review- IX Digital Asset Industry Index Series

2.1 ixCrypto Stablecoin Index
The number of constituents will remain at 5. Stablecoins comprise approximately 11.58% of the total crypto universe, and the ixCrypto Stablecoin Index covers approximately 95.08% of the 90-day average market capitalization within the provided Q3 stablecoin calculation universe.

Additions
No addition

Deletions
No deletion

3. Exchange Review
As a result of the exchange review, 10 exchanges passed the review process, which are as follows:

Passed Exchanges

1. Binance
2. Pionex
3. Billance ^(ADDITION)
4. LBank
5. Biconomy ^(ADDITION)
6. CoinW
7. Coinbase Exchange
8. Bybit
9. XT.COM ^(ADDITION)
10. Gate.io

Removed Exchanges

1. BitMart
2. OrangeX
3. KuCoin

The selected 10 exchanges will be used to generate each of the fair average prices for the IX indexes’ constituents. The exchange review covers volume rankings, exchange background checks, founders’ background checks, USD/BTC/USDT/USDC/USDe pair coverage, overconcentration rules, exchange API coverage checks, and stability, among other aspects, for an exchange.

For more details about our exchange selection criteria, please email info@ix-index.com. More information on the ixCrypto Indexes and IX Digital Asset Industry Indexes, including their constituents and constituents’ weights, is provided in the Appendices, or refer to the website https://ix-index.com/.

*Exclude stable coins and exchange coins that trigger conflict of interest (based on conflict-of-interest rule methodology 3.9, effective on Oct 2, 2020)
#As of 30th September 2026, based on the past 90 days average
XXXX (ADDITION) Newly introduced exchanges as of 2026 Q3

4. Changes in Index Advisory Committee Members

IX Asia Indexes is honored to welcome Ms. Jennifer Tan and Prof. Rujing Meng to IX Asia Index Advisory Committee (“the Committee”), effective 1 November 2026. Ms. Tan is Founder and CEO of Porrima Limited, and Prof. Meng is Associate Director of the Asia Case Research Centre (ACRC) at HKU Business School.

Prof. Yuk-fai Fong, will retire after serving on the Committee for over 5 years. Prof. Fong joined the Committee in July 2020 and has made valuable contributions to the development of IX Asia Indexes. IX Asia Indexes and the Committee would like to express their sincere gratitude to Prof. Fong and wish him well in his next endeavours.

An update on the Committee members will be available on follow-up corporate announcement and official webpage https://ix-index.com/committee.html.

Universe	All crypto coins traded in at least two different exchanges around the world
Selection Criteria	Cryptocurrencies ranking in the top 80% of cumulative full market capitalization (“MC”) coverage and within an acceptable range in accordance with the Volume Buffer Rule in terms of 90-day average trading volume
Number of Constituents	19 in Q3 2026
Launch Date	12th December 2018
Base Date	3rd December 2018
Base Value	1,000
Reconstitution Rule	If the coverage is below 75% or any of constituents is not within an acceptable range in accordance with the Volume Buffer Rule in terms of 90-day average trading volume, IXCI will be reconstituted to bring MC coverage back and do liquidity screening.
Reconstitution and Rebalancing Frequency	Quarterly and with a fast entry rule
Weighting Methodology	Free float adjusted market capitalization weighted with a cap of 40%
Currency	US Dollar
Dissemination	Every 5 seconds for 24×7 (On Bloomberg, Reuters and major information vendors)
Website	https://ix-index.com/
Bloomberg Page	IXCI

	Crypto	90-day-average- Market Cap	90-day-average- Volume	Cut-off Price	Cumulative Market Coverage	Weighting (%) After 40% Cap#
1	Bitcoin	$1,433,322,419,246	$27,700,843,799	$83,553.85	58.85%	40.00%
2	Ethereum	$264,142,166,596	$12,246,382,379	$2,683.68	69.69%	26.04%
3	BNB	$87,042,482,284	$1,359,745,505	$768.18	73.27%	8.13%
4	XRP	$77,547,602,977	$2,622,129,858	$1.4884	76.45%	7.46%
5	Solana	$52,626,782,109	$2,785,398,866	$117.99	78.61%	5.51%
6	TRON	$31,573,089,006	$462,898,079	$0.3374	79.91%	2.55%
7	Hyperliquid	$18,056,331,700	$681,695,943	$90.87	80.65%	1.81%
8	Zcash	$13,525,057,754	$882,197,324	$1,436.40	81.20%	1.93%
9	Dogecoin	$12,981,307,257	$818,755,105	$0.0945	81.74%	1.17%
10	Monero	$8,058,315,713	$107,635,539	$544.45	82.07%	0.81%
11	Chainlink	$7,594,375,758	$353,164,241	$14.36	82.38%	0.85%
12	Cardano	$7,198,864,548	$444,998,716	$0.2466	82.68%	0.72%
13	Stellar	$6,359,003,197	$205,299,555	$0.2263	82.94%	0.63%
14	Bitcoin Cash	$4,846,352,862	$198,458,933	$305.88	83.14%	0.49%
15	Gram (prev. Toncoin)	$3,990,280,102	$75,847,847	$1.4986	83.30%	0.34%
16	Litecoin	$3,897,223,315	$279,850,177	$67.17	83.46%	0.41%
17	Hedera	$3,295,190,109	$83,607,057	$0.1047	83.59%	0.37%
18	Avalanche	$3,232,704,303	$342,337,447	$10.93	83.73%	0.39%
19	Sui	$3,166,361,463	$444,530,770	$1.16	83.86%	0.39%

As of 30 September 2026

# Weighting (%) after 40% Cap is adjusted according to the cut-off price, the arrangement of order may not be the same as 90-day-average-Market Cap

Selection of index constituents is based on the past 90-day-average market capitalization and volume.

For the calculation methodology of the index, please refer to the “ixCrypto Index Methodology Paper” on our website

	Index Constituent	ixCrypto 5 EW Index	ixCrypto 5 SR Index	ixCrypto 10 EW Index	ixCrypto 10 SR Index	ixCrypto Altcoin 10 EW Index	ixCrypto Altcoin 10 SR Index
1	Bitcoin	20.00%	46.98%	10.00%	37.38%	–	–
2	Ethereum	20.00%	20.76%	10.00%	16.51%	10.00%	25.17%
3	BNB	20.00%	11.60%	10.00%	9.23%	10.00%	14.06%
4	XRP	20.00%	11.11%	10.00%	8.84%	10.00%	13.47%
5	Solana	20.00%	9.55%	10.00%	7.60%	10.00%	11.58%
6	TRON	–	–	10.00%	5.16%	10.00%	7.87%
7	Hyperliquid	–	–	10.00%	4.36%	10.00%	6.64%
8	Zcash	–	–	10.00%	4.49%	10.00%	6.85%
9	Dogecoin	–	–	10.00%	3.50%	10.00%	5.34%
10	Monero	–	–	10.00%	2.92%	10.00%	4.45%
11	Chainlink	–	–	–	–	10.00%	4.56%

As of 30 September 2026

Crypto	90-day-average Crypto Market Cap	90-day-average Crypto Volume	Index Level	Weight in BTC/ETH 50/50	Weight in BTC/ETH Proportional
Bitcoin	$1,433,322,419,246	$27,700,843,799	20186.84	50.00%	83.67%
Ethereum	$264,142,166,596	$12,246,382,379	23030.95	50.00%	16.33%

As of 30 September 2026

As of 30 September 2026

ixCrypto Index is first disseminated every 1-hour in May 2020. In November the same year, the dissemination is upgraded to every 15- second and made available to the world via the Nasdaq Global Index Data Service. In March 2021, ixBitcoin Index (“IXBI”) and ixEthereum Index (“IXEI”) are launched, and together with IXCI, are available to the world via Nasdaq. In April 2022, the index dissemination upgraded to every 5-second interval and made 24×7 since 23 June 2022. On 23 July 2024, a separate direct connection with Bloomberg is established to allow Bloomberg real time subscription with 10 indexes. Today, over 26 real-time indexes are available to customers on the IX Crypto Index API subscription and Bloomberg subscription. For free delayed IXCI, IXBI and IXEI, the indexes are available through Nasdaq Global Index Data Service (GIDS) and most major information vendors.

The vendor tickers are shown below:

Index Name	Bloomberg Ticker		NASDAQ	Reuters Ticker
	Real-time	Delayed
ixCrypto Index	IXCI	IXCI2	.IXCI	.IXCI
ixBitcoin Index	IXCBI	IXCBI2	.IXBI	.IXBI1
ixEthereum Index	IXCEI	IXCEI2	.IXEI	.IXEI1

On 7 October 2026, IX Asia indexes announced the discontinuation of all real-time dissemination due to continuous cybersecurity attack.

For further information about ixCrypto Index and other available indexes including IX Crypto spot price index series, please visit company official webpage https://ix-index.com.

The issuer is solely responsible for the content of this announcement.

About IX Asia Indexes and IX Asia Index Advisory Committee

IX Capital International Limited is an award-winning index and investment advisory company. The index business arm- IX Asia Indexes, providing real-time digital asset and innovative indexes, disseminated 24×7 globally and built on robust infrastructure. Since the launch of the first crypto benchmark index (“IXCI”) launched in Hong Kong in December 2018, the ixCrypto index series expand into 29 indexes designed for exchange futures products, mark-to-market, and fund managers’ portfolio construction purposes. To ensure the professionality and impartiality of the index methodologies and operations, IX Asia Indexes has established its index advisory committee with representation from different industries, including fund management, exchanges, brokerage, financial blockchain experts, crypto service providers, etc. The committee will meet quarterly a year to discuss matters relating to the IX Asia Indexes, including to review and to comment the data sources, methodologies, and operations of IX Asia Indexes, to provide guidance to the future development of new IX Asia Indexes and to handle other issues and decisions on an as-needed basis.

IX Asia Indexes was awarded the Fintech Award (wealth investment and management) 2019 and 2021 organised by ETNet. It as well won an award for Startup of the Year and Basic Technology (Big Data) from Hong Kong Fintech Impetus Awards 2022 by Metro Broadcast and KPMG. It also won Asia Pacific Enterprise Achievement Award 2024 by Echolade. IX Asia Indexes completed its IOSCO compliance statement and obtained ISO/IEC 27001:2022 UKAS certification.

Website: https://ix-index.com/

Advisory Committee: https://ix-index.com/committee.htm

About IX Crypto Indexes

The ixCrypto index (“IXCI”) is the first crypto index launched in Hong Kong. It was launched on 12 December 2018. It is denominated in USD with a base value of 1000 and a base date on 3 December 2018. Designed to be easy to understand while providing a good representation of the crypto market, ixCrypto index aims to cover the top 80% of the cumulative free-float adjusted market capitalization in the crypto universe and, at the same time, the crypto currencies should fall within the top liquid cryptos ranked by trading volume in the 90 days preceding the review date. The index is to be reviewed quarterly and with a fast entry rule. Real time indexes are disseminated every 5-second for 24×7 since 23 June 2022. Real time index data together with ixBitcoin Index and ixEthereum Index can be obtained from IX Asia Indexes Data Services and Bloomberg terminal on IXCI . For IXCI, IXBI and IXEI, the indexes are also available through Nasdaq Global Index Data Service (GIDS) with the tickers “IXCI”, “IXBI”, “IXEI”, with dissemination interval kept at 15-second unchanged.

• ModelSphere simplifies enterprise large-model deployment and operations and boosts peak throughput by up to 285% (nearly 4x the baseline).
• Building a more open, chip-agnostic foundation for AI at scale.
• Free and open source for enterprise users and available on Github now.

BEIJING, CHINA – Media OutReach Newswire – 16 October 2026 – Phancy Group Co., Ltd. (“Phancy” or “the Group”, stock code: 6682.HK), a leading full-stack enterprise-AI cloud services platform, together with RiseUnion Technology Co., Ltd. (“RiseUnion”), today announced the official launch of ModelSphere, a one-stop, production-grade AI deployment platform.

Free and open source for enterprise users, ModelSphere brings computing resource management, model deployment and runtime optimization together in a single platform. It lowers the barriers to deployment and operations, helping enterprises turn computing power more efficiently into secure, stable AI services ready for real-world business use.

As large models move into commercial deployment at scale, enterprises commonly face low resource utilization, a fragmented chip ecosystem, high deployment barriers and difficult tuning in production environments. ModelSphere aims to consolidate computing resource coordination, model deployment and performance optimization into a unified deployment and management workflow, reducing the duplicated effort enterprises spend on low-level system adaptation, resource scheduling and day-to-day operations.

Phancy believes enterprises should be able to put large models to work without extensive in-house expertise in complex areas such as driver compilation and hardware adaptation. ModelSphere is designed to bridge this gap, enabling enterprises to integrate a wide range of open-source large models into core business processes while allowing technical teams to focus on application development and business needs.

Four Core Advantages of ModelSphere

• Simplified deployment and stable model services: ModelSphere provides a graphical console and pre-built deployment capabilities that reduce the environment-configuration code developers need to write, helping them quickly stand up inference services for large models and simplifying deployment across different chip clusters. Built-in enterprise-grade capabilities, including automatic elastic scaling, prefill-decode (PD) disaggregated deployment, three-tier KV caching, high-availability load balancing and automatic stream resumption after service interruptions, keep model services running stably in production.
• Continuous automated tuning for higher efficiency: The platform’s built-in AutoTune intelligent model scheduling strategy, combined with adaptive load-balancing scheduling that leverages hardware acceleration, improves request-handling capacity and time to first token (TTFT) while lowering inference cost per token. Built-in AutoTune boosts peak throughput by around 285% compared with the baseline, increasing overall performance to nearly four times the previous level and making full use of the available computing power.
• Unified management of diverse chips without repeated adaptation: Integrated with the EngineX inference engine, ModelSphere supports and is deeply optimized for a wide range of AI accelerators. It enables unified and mixed scheduling of all computing resources, including Huawei Ascend, Iluvatar CoreX, Moore Threads and Hygon DCU, so users do not need to rewrite low-level code for each chip.
• Continuous optimization for mainstream models and faster deployment: The ModelSphere team closely tracks iterations in the open-source community and has already adapted and optimized the platform for leading models, including DeepSeek-V4/V4-Flash, Qwen, Kimi, MiniMax and GLM. New models can be deployed quickly after release and tuned to production-grade performance, helping enterprises put the latest models to work in real business scenarios.

How ModelSphere Fits into the AI Stack

At the technical level, ModelSphere works alongside inference engines such as vLLM and SGLang. While inference engines improve computing efficiency on individual servers, ModelSphere handles management and optimization at the cluster-architecture level, including load- and cache-aware request routing, a unified KV cache pool, quality-of-service (QoS)-based automatic scaling, automatic stream resumption after service interruptions, automated performance tuning based on live production data, runtime monitoring and service management. Together, these ensure high performance and high availability in production environments.

By going open source, ModelSphere makes Phancy’s engineering capabilities for large-model deployment and optimization available to more enterprises and developers, and brings together industry partners to continuously expand support for different chips and models. This will reduce hardware adaptation barriers and lower the threshold for large-model adoption, helping enterprises make the most of their existing computing resources and efficiently unlock the commercial potential of heterogeneous computing.

Availability

ModelSphere is now available on GitHub at https://github.com/modelsphere/modelsphere under the Apache 2.0 license.
Hashtag: #Phancy #ModelSphere #AI

The issuer is solely responsible for the content of this announcement.

About Phancy Group

Phancy Group (6682.HK) is a leading full-stack AI cloud services platform, providing comprehensive solutions for the AI 2.0 era. Our offerings include SageAIOS, HAMi vGPU and ModelHub XC, delivering efficient and scalable AI infrastructure with end-to-end capabilities. We provide a complete solution from heterogeneous compute resource management and optimization to the deployment of intelligent agent models. These solutions empower digital transformation across a wide range of industries, supporting our vision of building a large-scale and efficient “Token Factory.”

Guided by the mission of “AI for Everyone” and positioned as the “Navigator of AI,” Phancy Group is committed to becoming a global leader in Artificial General Intelligence.